Table 1. Cytotoxicity, in vitro activity, and specificity of fusion inhibitory peptides.
| Peptide | Cytotoxicity in monolayer culture | Efficacy in plaque reduction assay vs. HPIV3 |
|
|---|---|---|---|
| CC50 (nM)a | IC90 (nM)b | IC50 (nM)b | |
| VG | >10,000 | 280 ± 247 | 1 |
| VG-Chol | 10,000 | 0.7 ± 0.26 | 0.015 ± 0.07 |
| VG-PEG4-Chol | 4,500 | 0.7 ± 0.007 | 0.03 ± 0.04 |
| VG-PEG24-Chol | 1,300 | 0.1 ± 0.0003 | 0.007 ± 0.007 |
| Chol-VG | 9,000 | 1.7 ± 0.42 | 0.06 ± 0.035 |
| Chol-PEG4-VG | >10,000 | 0.1 ± 0.0001 | <0.0007 |
| HRCFIV PEG 24 Chol | 9,000 | >9,000 | >9,000 |
| HRCMV PEG 24 Chol | 2,000 | >2,000 | >2,000 |
| HAFLU PEG 24 Chol | 3,000 | >3,500 | >3,500 |
aCompound concentration required to reduce the viability of mock-infected Vero cells by 50%, as determined by MTT.
bCompound concentration required to achieve 50% or 90% plaque reduction for HPIV3.